| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
IR-820 does not have a classical drug target. Its function is based on its physical properties as a fluorescent dye. It acts as a contrast agent for near-infrared fluorescence imaging (NIRF). The compound accumulates in tissues and provides contrast for imaging due to its strong NIR absorption and emission. It can also be used for photothermal therapy due to its light-absorbing properties.
|
|---|---|
| ln Vitro |
Guidance (The following is our proposed protocol. This protocol provides guidance only and should be changed to match your individual needs). Internal [1]: 1. Freshly combine powdered IR-820 with phosphate buffer saline (PBS) to a final concentration of 0.2 mM, and inject 100 μL of this solution into the experimental animals. 2. Use 2 groups of four mice. The first group is injected with IR-820 through the tail vein, whereas the second group is injected intraperitoneally. 3. The maximal excitation and emission wavelengths of IR-820 are 710 nm and 820 nm respectively. Theory 8 days.
IR-820 is not typically used in traditional pharmacological activity assays. Its in vitro activity is related to its fluorescent properties and its ability to label cells or tissues. It is used in in vitro imaging studies where cells are incubated with the dye and visualized using NIR fluorescence microscopy. The compound shows good stability and color rendering in solution. It is also used in photothermal therapy experiments in vitro. |
| ln Vivo |
IR-820 is used for in vivo near-infrared fluorescence imaging as a blood pool contrast agent. It allows for the detection and quantification of diseased tissue in live animals. The dye is typically administered intravenously, and its distribution can be monitored using NIR imaging systems. Its fluorescence penetration properties enable deep-tissue imaging. IR-820 can also be used for photothermal therapy in vivo by irradiating the target area with an 808 nm laser.
|
| Enzyme Assay |
As a fluorescent dye, IR-820 does not have a standard enzyme/receptor binding assay. Its properties are evaluated based on its spectroscopic characteristics, such as absorption and emission spectra, fluorescence quantum yield, and photostability. The dye's stability in biological fluids and its binding to serum proteins may be assessed, but these are not classical binding assays.
|
| Cell Assay |
In vitro cellular experiments with IR-820 involve adding the dye to cell cultures and incubating for 30-60 minutes. The cells are then imaged using NIR fluorescence microscopy to assess dye uptake and distribution. For photothermal therapy studies, cells are incubated with IR-820 and then irradiated with an 808 nm laser to evaluate cell killing efficacy. The dye is typically used at concentrations of 10-50 µM for in vitro experiments.
|
| Animal Protocol |
In vivo animal experiments with IR-820 involve intravenous administration of the dye, typically at doses of 0.5-1 mg/kg. Imaging is performed using near-infrared imaging equipment to detect the dye's fluorescence signal. For photothermal therapy, tumors are irradiated with an 808 nm laser at intensities of 1-2 W/cm² for 5-10 minutes after dye administration. The dye's distribution and therapeutic efficacy are then assessed.
|
| ADME/Pharmacokinetics |
IR-820 has a molecular weight of 849.47 and a molecular formula of C46H50ClN2NaO6S2. It is soluble in water and DMSO. The compound is sensitive to light and should be stored in the dark at -20°C for long-term storage. For in vivo imaging, it is typically administered intravenously at doses of 0.5-1 mg/kg. Its pharmacokinetics are characteristic of NIR dyes, with rapid distribution to tissues.
|
| Toxicity/Toxicokinetics |
Toxicological data for IR-820 is not detailed in the provided sources. As a fluorescent dye used for imaging and photothermal therapy, it is generally considered to have low toxicity at the concentrations used for these applications. The compound is for research use only and is not intended for human therapeutic use. Standard safety precautions should be followed when handling.
|
| References | |
| Additional Infomation |
IR-820 (New Indocyanine Green) is a near-infrared tricarbocyanine dye used as a blood pool contrast agent for medical diagnostics and research. It has excellent stability, good color rendering, and superior fluorescence penetration. With maximal excitation and emission at 710 nm and 820 nm, respectively, it enables deep-tissue imaging. The compound is also used for photothermal therapy applications. It is available for research purposes from various chemical suppliers.
|
| Molecular Formula |
C46H50CLN2NAO6S2
|
|---|---|
| Molecular Weight |
849.4738
|
| Exact Mass |
848.27
|
| CAS # |
172616-80-7
|
| PubChem CID |
53249358
|
| Appearance |
Brown to dark brown solid powder
|
| Melting Point |
>300ºC
|
| LogP |
12.046
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
58
|
| Complexity |
1710
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)[O-])/C=C/C4=C(/C(=C\C=C\5/C(C6=C(N5CCCCS(=O)(=O)[O-])C=CC7=CC=CC=C76)(C)C)/CCC4)Cl)C.[Na+]
|
| InChi Key |
RANIQVAJHXBIAY-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C46H51ClN2O6S2.Na/c1-45(2)40(48(28-9-11-30-56(50,51)52)38-24-20-32-14-5-7-18-36(32)42(38)45)26-22-34-16-13-17-35(44(34)47)23-27-41-46(3,4)43-37-19-8-6-15-33(37)21-25-39(43)49(41)29-10-12-31-57(53,54)55;/h5-8,14-15,18-27H,9-13,16-17,28-31H2,1-4H3,(H-,50,51,52,53,54,55);/q;+1/p-1
|
| Chemical Name |
sodium;4-[(2E)-2-[(2Z)-2-[2-chloro-3-[(E)-2-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonate
|
| Synonyms |
IR820; IR 820; IR-820
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~5.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1772 mL | 5.8860 mL | 11.7720 mL | |
| 5 mM | 0.2354 mL | 1.1772 mL | 2.3544 mL | |
| 10 mM | 0.1177 mL | 0.5886 mL | 1.1772 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
